Lupin has incorporated wholly owned subsidiary ‘Lupin Manufacturing Solutions’ for undertaking contract development and manufacturing activities.
Earlier, Lupin’s wholly owned subsidiary in Australia, Generic Health, had received approval for Tiotropium 18 micrograms powder for inhalation in capsules for use with LupinHaler, its bioequivalent version of SPIRIVA tiotropium (as bromide monohydrate) powder for inhalation from Therapeutic Goods Administration (TGA). The product will be manufactured at Lupin’s Pithampur facility in India.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.